FAST Program

The FAST Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Through the program, 8-12 companies are directly served each year; an additional 20-30 startup applicants receive referrals and other advising to help them become “FAST”- ready.

Since launching in Fall 2013, FAST program cycles have generated over 8000 advisory hours valued at over $1,900,000 for the 79 companies who have been through the program. Since participating in FAST, these companies have raised $1.9 billion and created 500 new jobs, more than tripling their workforce. Thirty of these companies have secured Series A investments, 20 have concluded strategic partnerships.

Previous FAST Bay Area Companies

Abalone Bio
Algen Biotechnologies
Altay Therapeutics
Amaryllis Nucleics
Applied Molecular Transport
Argonaut Genomics
ARIZ Precision Medicine
Atropos
Bikanta
BioAmp Diagnostics
C. Light Technologies
Cairn Biosciences
CellFE
Centauri Therapeutics
Ciel Medical
Circularis
Convalesce
Correlia Biosystems
Dark Horse Solutions
Device Farm
Eidos Therapeutics
Empire Biotechnologies
Encellin
EpiBiome
Eysz
Facile Therapeutics
Fauna Bio
GigaGen
Glialogix
Hepatx
IGIstat
Inflammatix
InnovaNutra
Ligandal
Linnaeus Bioscience
LogicInk
Magnetic Insight
Mantra Bio
Matrubials
Melio
Metis Biosciences
MicroSynbiotiX
N1 Life

Nano Precision Medical
Navega Therapeutics
NeuroSave
NeuScience
Nodexus
Omniox, Inc.
Oomni
Oppilotech
Paragon Genomics, Inc.
Pheronym
Phi Therapeutics
Pinpoint
Purigen
Raydiant Oximetry
Raydiant Oximetry
Reservoir Neuroscience
Respiralabs
Rex Animal Health
Sandstone Diagnostics
Sardona Therapeutics
SciBac
Seismic Bio
Serenity Bioworks
Shasqi, Inc.
Siolta
SmarterABX
STATegics
SUMO Biosciences
SyntheX
TheraBiol
Trellis Biosciences
Underdog Pharmaceuticals
Unnatural Products
Valitor
Valley Fever Solutions
Vanguard Therapeutics
Whole Biome
Xcell Biosciences, Inc.
X-Therma
YourChoice
Zephyrus Biosciences
Ziteo Medical

Supported By:

This program is part of the CLS’ Racial and Social Equity Initiative, a unified effort to do more for the under-served and under-represented, focusing on the most critical need to address inequality and create opportunities for our current and future innovators to succeed. #WeCommitToChange.